产品名称 | NebuSelect™ Recombinant Human CD84/SLAMF5, Avi-His-tag |
---|---|
目录号 | NBL-242859 |
别名 | CD84/SLAMF5; Hly9-beta; CD84; SLAMF5; LY9B; CD84 molecule; DKFZp781E2378 |
外观 | see COA |
分子量 | Lys22-Gly225 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q9UIB8-1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242859-100ug | 100ug | Inquire | Inquire | |
NBL-242859-1mg | 1mg | Inquire | Inquire | |
NBL-242859-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human CD84/SLAMF5, Avi-His-tag
Catalog#:
NBL-242859
Description:
NebuSelect™ Recombinant Human CD84/SLAMF5, Avi-His-tag(Cat#NBL-242859) is expressed in HEK293 with His tag and Avi tag at the C-Terminus.It contains Lys22-Gly225.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 25.4 kDa. Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result.
Target Name:
CD84/SLAMF5; Hly9-beta; CD84; SLAMF5; LY9B; CD84 molecule; DKFZp781E2378
Target Information:
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5 B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells.
Amino Acid Sequence:
Lys22-Gly225
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.